Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.
Bristol Myers Squibb (NYSE: BMY) generates frequent news across drug development, regulatory milestones, clinical data and corporate actions, reflecting its role as a global biopharmaceutical company focused on serious diseases. News coverage on this page centers on how the company’s cardiovascular, oncology, hematology, immunology and neuroscience programs progress from clinical trials to regulatory decisions and real-world use.
Recent updates have highlighted positive Phase 3 trial results for Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy in the SCOUT-HCM study, including statistically significant improvements in left ventricular outflow tract gradients and safety findings consistent with adult experience. Other headlines feature regulatory developments such as the U.S. Food and Drug Administration granting priority review to an Opdivo (nivolumab) plus chemotherapy combination for previously untreated advanced classical Hodgkin lymphoma, and the FDA’s approval of Breyanzi (lisocabtagene maraleucel; liso-cel) for adults with relapsed or refractory marginal zone lymphoma.
Investors and followers of BMY can also expect news on hematology research presented at major medical meetings, including data on investigational targeted protein degradation agents like golcadomide and BMS-986458, and long-term follow-up results for Breyanzi in large B-cell and follicular lymphomas. Corporate and financial items appear as well, such as dividend declarations, debt offerings, tender offers for outstanding notes, and presentations at healthcare investment conferences.
This news feed brings together company press releases, clinical trial readouts, regulatory updates, access and affordability agreements, and SEC-reported events. For users tracking BMY stock, it offers a single place to review how Bristol Myers Squibb’s pipeline, marketed products and capital markets activity evolve over time. Bookmark this page to quickly review new trial results, FDA decisions, access initiatives and financial disclosures related to Bristol Myers Squibb.
Bristol Myers Squibb (NYSE: BMY) and Nektar Therapeutics (NASDAQ: NKTR) reported disappointing results from the Phase 3 PIVOT IO-001 study evaluating bempegaldesleukin plus Opdivo versus Opdivo alone in metastatic melanoma. The independent Data Monitoring Committee found no significant benefits in progression-free survival (PFS) or objective response rate (ORR). Consequently, the companies decided to unblind the trial and halt enrollment for the related PIVOT-12 study. The focus will now shift to ongoing studies in renal cell carcinoma and bladder cancer.
Bristol Myers Squibb (NYSE:BMY) will report its first quarter 2022 financial results on
Bristol Myers Squibb (NYSE: BMY) announced its participation in investor conferences on
Bristol Myers Squibb (NYSE: BMY) announced FDA approval for Opdivo® (nivolumab) in combination with platinum-doublet chemotherapy as the first immunotherapy-based treatment for resectable non-small cell lung cancer (NSCLC) in the neoadjuvant setting. This approval follows the Phase 3 CheckMate -816 trial, demonstrating a 37% reduction in progression risk and a median event-free survival of 31.6 months with Opdivo, compared to 20.8 months for chemotherapy alone. The approval enhances treatment options prior to surgery, regardless of PD-L1 status.
Bristol-Myers Squibb Company (NYSE:BMY) announced the accepted amounts and pricing for their 22 separate cash offers to purchase notes. Key details include:
- Majority of 2025 and 2026 Pool Notes accepted with yields of 1.961% and 1.842% respectively.
- A total principal amount of $1.6 billion accepted from the 2029 Pool Notes with a yield of 2.356%.
- The Offers are set to expire on March 15, 2022, unless extended.
All accepted Notes will be cancelled, with the Early Settlement Date occurring on March 4, 2022.
Bristol-Myers Squibb (NYSE: BMY) announced early results for its tender offers, with a new maximum purchase price up to $4 billion for multiple series of notes. As of March 1, 2022, significant tendering was reported, including $821.88 million for 2025 notes and $1.45 billion for 2026 notes. The offers include various pools, such as 2025, 2026, and high coupon notes. The deadline for acceptance is set for March 15, 2022. The company will issue a press release on March 2, 2022, detailing the accepted amounts and yields.
Bristol Myers Squibb (NYSE: BMY) has declared a quarterly dividend of
Dragonfly Therapeutics has achieved a significant milestone in its Phase 1 clinical trial for the DF6002/BMS-9896415 IL-12 program, receiving a milestone payment from Bristol Myers Squibb (BMY). DF6002, an investigational monovalent IL-12 immunoglobulin Fc fusion protein, aims to enhance anti-tumor responses in patients with advanced solid tumors. The trial, which began in July 2020, focuses on assessing the safety and anti-tumor activity of DF6002. With Bristol Myers Squibb responsible for development and commercialization, Dragonfly stands to gain further milestone payments and royalties on net sales.
Bristol Myers Squibb has announced the FDA's acceptance of its supplemental Biologics License Application for Opdivo plus chemotherapy, targeting resectable non-small cell lung cancer (NSCLC). This application, based on the CheckMate -816 trial results, has received Priority Review status, with a PDUFA goal date set for July 13, 2022. The CheckMate -816 trial indicated significant improvements in pathologic complete response and event-free survival when compared to chemotherapy alone. If approved, this would be the first immunotherapy-based neoadjuvant treatment option for NSCLC in the U.S., addressing a critical need in early-stage lung cancer treatment.
Bristol Myers Squibb (NYSE:BMY) has received a positive opinion from the CHMP for the combination therapy of Opdivo (nivolumab) and chemotherapy for first-line treatment of adults with unresectable advanced esophageal squamous cell carcinoma (ESCC) with PD-L1 expression ≥1%. This recommendation is based on the Phase 3 CheckMate -648 trial, which showed a significant overall survival benefit (median 15.4 months vs. 9.1 months) for the combination versus chemotherapy alone. The European Commission will review this opinion next.